
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.

Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.

WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.

Heidi Overton ran into opposition from Republican senators concerned about her role in setting White House vaccine policy.

Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.

The FDA approved Cosentyx for polymyalgia rheumatica after 40.5% of trial patients reached sustained remission at week 52 vs. 20.5% on placebo.

SBE303, a Nectin-4 ADC for previously treated bladder cancer, is in phase 1 as the company advances SB27, its proposed Keytruda biosimilar.

NeosRx CEO Jeff Dunn, Pharm.D., MBA, explains how 340B claims can disadvantage PBMs because of loss of rebates..

A CMS rule moving insulin pumps and CGMs into Medicare bidding by 2028 has drawn a coalition letter and a Senate bill seeking delay.

Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.

A mouse study found that how much antigen sits on a vaccine’s surface, not just its size or shape, drives the T-cell response.

Out-of-pocket costs may affect more than patients’ wallets, raising anticipated pain and discouraging some from scheduling care, according to a new study out of Carnegie Mellon University.

The FDA cleared Teva’s Igalmi sublingual film for at-home use, the first at-home approved option for agitation tied to schizophrenia or bipolar disorder.

A system can cover its population and still struggle with access, workforce capacity and the cost of care

Drug launch prices are rising, but Benjamin N. Rome, M.D., M.P.H., and colleagues found no evidence manufacturers raised them in response to the Inflation Reduction Act.

What would it mean to treat vision, hearing and dental utilization as population health metrics, the same way we track vaccination rates or chronic disease management gaps?

Naik says a strong recommendation for infliximab and a call for routine pain assessment are the HS guideline changes most likely to change clinical practice.

New guidelines for care of hidradenitis suppurativa advise against radiotherapy for children and adolescents, citing its long-term risks and safer treatment options.

Hidradenitis suppurativa was long thought to be a rare condition, but global data put the prevalence at 1%, says Naik, co-chair of the new AAD-HS Foundation guidelines for the disease.

"Payviders" are responsible for the cost of avoidable readmissions and emergency room visits, but they lose sight of patients once they go home.

Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.

Only 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.

Jamilia Sherls, DNP, says health systems should track vaccine coverage closely and look to AAP schedules if federal guidance isn't evidence-based.

Model N's Jesse Mendelsohn explains why drug manufacturers argued that a 340B rebates instead of upfront discounts will avoid an overlapping maximum fair price and 340B discounts

People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.

Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.

Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.

A study of 1,068 adults found whole-blood NAD fell in those with cardiovascular disease and hypertension but did not decline with age.

Adding Sunharbo (asundexian), a first-in-class factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.

In this discussion, University College London colleagues Joshua Stott, Ph.D., professor of aging and clinical psychology and research assistant Lucy Corrigan, who led the work while at the University of Liverpool, talk about their recent meta-analysis linking ADHD to a higher risk of death from all causes, including suicide, injury and natural causes.

The American Academy of Sleep Medicine’s first update since 2007 favors generic drugs, caffeine, light and naps, and advises against benzodiazepines.